Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 9, 2026, 11:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 80 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cellular Rejection Clear all
Completed No phase listed Observational

Proteomic Analysis Reveals Innate Immune Activity In Intestinal Transplant Dysfunction

NCT01140152
View directory record Official record
Conditions
Intestinal Transplant, Cellular Rejection
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jun 9, 2026, 11:44 PM EDT
Completed No phase listed Observational

Eliminating the Need for Pancreas Biopsy Using Peripheral Blood Cell-free DNA

NCT04166149
View directory record Official record
Conditions
Transplant;Failure,Kidney, Transplant; Failure, Pancreas, Rejection Acute Renal, Rejection Acute Pancreas
Interventions
dd-cfDNA Blood Test
Diagnostic Test
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Jun 9, 2026, 11:44 PM EDT
Not listed No phase listed Observational

Heartsbreath Test for Heart Transplant Rejection

NCT01397812
View directory record Official record
Conditions
Heart Transplant Rejection
Interventions
BreathScanner 1.0, BreathLink
Device
Lead sponsor
Menssana Research, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
5
States / cities
Beverly Hills, California • Stanford, California • Newark, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Jun 9, 2026, 11:44 PM EDT
Active, not recruiting Phase 1 Interventional

Immunological Tolerance in Patients With Mismatched Kidney Transplants

NCT05806749
View directory record Official record
Conditions
End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
Interventions
Donor CD34+, CD3+. and belumosudil
Combination Product
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Jun 9, 2026, 11:44 PM EDT
Completed No phase listed Observational

Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection

NCT03984747
View directory record Official record
Conditions
Transplant Rejection, Allograft Rejection, Complications
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
2 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
4
States / cities
San Carlos, California • San Diego, California • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Jun 9, 2026, 11:44 PM EDT
Recruiting No phase listed Observational

Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection

NCT05084768
View directory record Official record
Conditions
Acute Rejection of Renal Transplant, Graft Failure
Interventions
Donor-derived cell-free DNA
Diagnostic Test
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jun 9, 2026, 11:44 PM EDT
Active, not recruiting Phase 4 Interventional

Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients

NCT05325073
View directory record Official record
Conditions
Liver Transplant Rejection
Interventions
Erythropoietin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 74 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Jun 9, 2026, 11:44 PM EDT
Completed Phase 2 Interventional Results available

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

NCT00096161
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Graft Versus Host Disease, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Waldenstrom Macroglobulinemia
Interventions
Cyclosporine, Mycophenolate Mofetil, Pentostatin, Therapeutic Allogeneic Lymphocytes
Drug · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
4
States / cities
Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Jun 9, 2026, 11:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling

NCT02178943
View directory record Official record
Conditions
Cardiac Transplant Failure, Cardiac Transplant Rejection, Heart Diseases
Interventions
Not listed
Lead sponsor
CareDx
Industry
Eligibility
15 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
28
States / cities
Beverly Hills, California • Los Angeles, California • Stanford, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Jun 9, 2026, 11:44 PM EDT
Completed No phase listed Observational

Study of Heart Transplant Rejection

NCT00042614
View directory record Official record
Conditions
Heart Transplantation
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Bethesda, Maryland • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 9, 2026, 11:44 PM EDT
Active, not recruiting Phase 2 Interventional

Mesenchymal Stromal Cells in Living Donor Kidney Transplantation

NCT03478215
View directory record Official record
Conditions
Renal Transplantation, Mesenchymal Stem Cells
Interventions
Mesenchymal Stromal Stem Cells (MSCs) Infusion, Normal Saline (Placebo) Infusion
Biological · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Jun 9, 2026, 11:44 PM EDT
Completed Phase 1 Interventional

Tolerance by Engaging Antigen During Cellular Homeostasis

NCT03504241
View directory record Official record
Conditions
Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient
Interventions
Donor-derived Mesenchymal Stromal Cells, alemtuzumab, belatacept, sirolimus, mycophenolate mofetil, mycophenolate acid, prednisone
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jun 9, 2026, 11:44 PM EDT
Active, not recruiting Not applicable Interventional

A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy

NCT06414603
View directory record Official record
Conditions
Heart Transplant Failure and Rejection
Interventions
The Prospera™ Test
Diagnostic Test
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 9, 2026, 11:44 PM EDT
Withdrawn Phase 4 Interventional

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

NCT02130817
View directory record Official record
Conditions
End Stage Renal Disease, Antibody Mediated Rejection
Interventions
Belatacept, Tacrolimus withdrawal, Plasmapheresis/Intravenous Immunoglobulin G, Thymoglobulin (ATG), Myfortic, Steroids
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 16, 2018 · Synced Jun 9, 2026, 11:44 PM EDT
Completed Phase 3 Interventional

Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants

NCT03363945
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
MDR-101
Biological
Lead sponsor
Medeor Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
18
States / cities
Loma Linda, California • Los Angeles, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Jun 9, 2026, 11:44 PM EDT
Not listed Phase 4 Interventional

Single Dose rATG for Renal Allograft Rejection

NCT02102854
View directory record Official record
Conditions
Acute (Cellular) Renal Allograft Rejection
Interventions
rATG
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Jun 9, 2026, 11:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

HLA-Identical Sibling Renal Transplant Tolerance

NCT00619528
View directory record Official record
Conditions
Immunosuppression, Kidney Transplantation, Graft Rejection
Interventions
Infusion of Donor Hematopoietic Stem Cells and Campath-1H
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 9, 2026, 11:44 PM EDT
Not listed Phase 2 Interventional

Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant

NCT00472329
View directory record Official record
Conditions
Graft Failure
Interventions
Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donors, fludarabine, TBI
Procedure · Drug
Lead sponsor
Colorado Blood Cancer Institute
Other
Eligibility
18 Years to 74 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 29, 2014 · Synced Jun 9, 2026, 11:44 PM EDT
Completed Phase 1 Interventional

Trial of Adoptive Immunotherapy With TRACT to Prevent Rejection in Living Donor Kidney Transplant Recipients

NCT02145325
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Expanded Tregs
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Jun 9, 2026, 11:44 PM EDT
Recruiting Phase 1 Interventional

Treatment of Antibody-Mediated Rejection (ABMR) With CarBel

NCT06918990
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Carfilzomib, Belatacept
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 9, 2026, 11:44 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants

NCT05525507
View directory record Official record
Conditions
End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
Interventions
Conditioning and Stem cell infusion
Combination Product
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Jun 9, 2026, 11:44 PM EDT
Withdrawn Phase 2 Interventional

A Safety and Efficacy Study of FCR001 Cell Therapy in Previously Transplanted Living Donor Kidney Recipients

NCT01649388
View directory record Official record
Conditions
Kidney Transplantation
Interventions
FCR001
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Jun 9, 2026, 11:44 PM EDT
Completed Phase 2 Interventional Results available

Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies

NCT00307125
View directory record Official record
Conditions
Kidney Transplant, Kidney Transplant Recipient, Graft Function/Survival, de Novo HLA Antibodies Development
Interventions
Rituximab plus immunosuppression, Placebo plus immunosuppression
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 70 Years
Enrollment
757 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
17
States / cities
Birmingham, Alabama • San Francisco, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Jun 9, 2026, 11:44 PM EDT
Recruiting Early Phase 1 Interventional

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

NCT06398457
View directory record Official record
Conditions
Hematologic Malignancy, Bone Marrow Transplant Rejection, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Acute Lymphoblastic Leukemia (ALL), Adult, Multiple Myeloma, Aplastic Anemia, Lymphoma, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Chronic Myeloid Leukemia, Myelofibrosis
Interventions
Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Jun 9, 2026, 11:44 PM EDT